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Los Angeles, CA
Motivation: Lung cancer is the leading cause of cancer
death, and lung adenocarcinoma (LUAD) is its pre-
dominant histological subtype. Fifteen single nucleotide
polymorphisms (SNPs) have been signiﬁcantly associ-
ated with LUAD risk in genome-wide association
studies (GWAS). However, because most GWAS SNPs
reside in non-coding regions and are co-inherited with
hundreds of SNPs in linkage disequilibrium (LD), which
SNPs play a causal role in disease development remains
largely unknown. We hypothesized that some of these
SNPs affect oncogenic transcriptional programs by
modulating the activity of gene enhancers in alveolar
epithelial cells (AECs), the purported cells of origin for
LUAD.
Methods: To test this hypothesis, we overlaid epigenomic
features of primary human AECs over the locations of in-
dex LUAD risk SNPs and associated high LD SNPs. Lucif-
erase assays for enhancer activity were performed for
candidate SNPs that were predicted to disrupt transcrip-
tion factor (TF) binding sites in loci marked by features of
active enhancers. Expression quantitative trait loci (eQTL)
analysis was also performed using The Cancer Genome
Atlas (TCGA) dataset and the online Genotype-Tissue
Expression (GTEx) Portal to identify potential target genes
of each SNP-enhancer pair.
Results: Thirty-three LUAD risk-associated SNPs map-
ped to putative AEC enhancer regions. TF binding site
prediction suggests that numerous SNPs might alter the
binding afﬁnity of TFs implicated in lung cancer,
including RXRA and NKX2-1. Luciferase assays indicate
that two of the SNPs signiﬁcantly affect enhancer activity
in lung cancer cell lines. eQTL analyses link each of the
putative enhancers to candidate target genes, including
both known oncogenes and genes not previously asso-
ciated with lung cancer.
Conclusions: Taken together, our analyses provide new
mechanistic insight into long-known associations be-
tween non-coding SNPs and LUAD outcomes, and may
ultimately yield more effective and personalized strate-
gies for lung cancer risk assessment, prevention, and
treatment.Magnetic nanocubes for selective
capture of circulating tumor cells
in NSCLCDhananjay Suresh, Anandhi Upendran,
Raghuraman Kannan University of Missouri,
Columbia, MO
Non-small cell lung cancer (NSCLC) is the leading cause for
cancer related mortality rates in the US, often associated
with 20-35% response rate and a w10 month median
survival time. Currently, tissue diagnostics is performed
using immunohistochemistry, FISH, and PCR for staging
and treatment planning. In vivo imaging such as PET or CT
is also used to detect the severity of NSCLC. NSCLC
metastasize by spreading primary tumor cells to distant
organs. Therefore, it is possible to isolate circulating tu-
mor cells (CTC) in patients’ blood, and as the cells origi-
nate from tumor, detailed genetic evaluation about the
tumor could be performed. Isolation and study on circu-
lating tumor cells is slowly evolving as liquid biopsy of
cancer. In fact, CTC detection technique is emerging as
prognostic markers to identify treatment response in
NSCLC patients. The current CTC capture methodology
involves cell search technologies, predominantly relying
on EpCAM expression based detection. However with the
discovery of tumor heterogeneity and consequent impact
on clinical treatment, it is important to detect patients
with CTCs early on, based on their genetic alterations.
BothHER2 (2-5%mutation incidence) andEGFR (10-35%
mutation incidence) overexpression have been pro-
nounced in patient biopsies and their exclusivity in in-
dividuals has been seen as a prerequisite in
chemotherapeutic selection and dose. Moreover there is
no standardized process to selectively identify CTCs based
on HER2 and EGFR surface expressions. While EGFR and
resistant mutations has been prominent, in the under-
standing ofNSCLC characterization, HER2 is relatively less
explored and frequently associated with breast cancer
detection. Recent studies show that HER2 expressions
correlate with metastases and disease free survival.
Overall this fact leads us to believeHER2markers could be
present in CTCs. Therefore, we are developing magnetic
iron nanocubes (FeNC) functionalized with either Her-
ceptin or Cetuximab as markers. These CTC markers can
be correlated with tumor heterogeneity and decide ther-
apeutic targets forﬁrst line and second line treatment. Our
approach involves cell sensing using magnetic nano-
particles (MNP), counting and subsequent separation of
live A549 (HER2þve; EGFRþve) and HCC827 (HER2 -ve;
EGFRþve) cells from a mixture for further processing. In
our current work we have synthesized HER2 and EGFR
receptor targeting iron oxide nanoparticles (50nm) that
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extended periods of time. The MNPs are incubated with
cells in 1X PBS for 3h for receptor binding at 37C after
which particles bound to cells are magnetically separated
with a pull force of 57 lbs. Cells are then washed and
counted using an automated algorithm. Thewhole process
has been optimized to a minimum cell population of 100
and can be theoretically reduced to a 2h process which
makes this extremely effective for clinical evaluations and
straightforward. Similar protocol was used when the cells
were spiked in blood plasma and captured. Our data
suggests strong correlation between number of A549 cell
captured when Herceptin conjugated MNPs are used
(96%difference vs HCC827), while Cetuximab conjugated
MNPs pull both HCC827 aswell as A549 (31%difference).
We expect to reduce the cell capture limit to less than 10
cells in further experiments as required for patient testing.
In conclusion, our results show that MNP based sensing
allows both cell marker characterization as well as cap-
ture simultaneously. The nanocubes allow better charac-
terization of HER2 and EGFR positive metastatic
cell subpopulations and provide easier prediction of tu-
mor heterogeneity without resorting to invasive proce-
dures.
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NSCLC is diagnosed in an estimated 220,000 patients
each year with ﬁve-year overall survival rates of 16
percent. A recent report conﬁrmed that 16 percent of
NSCLC patients carry oncogenic KRAS mutation. Patients
with KRAS mutation often harbored in wild-type EGFR
tumors, are resistant to Tyrosine Kinase Inhibitors (TKI).
A potent drug targeted against KRAS mutation has not
yet been developed and the objective response rate with
the current standard of care is a meager three percent.
Interestingly, KRAS knockdown using siRNA sensitizes
tumor to TKI with a good response rate. Retroviral
vectors, liposomes, polymeric particles and metallic
nanoparticles have been used as carriers to deliver
siRNA within cancer-site. However, protecting siRNA
from serum degradation and cytoplasmic delivery are
two major issues. Also, in most cases, a mere siRNA
mediated oncogene knockdown does not have signiﬁcantimpact on the cancer cell apoptosis since the cells adapt
to another effector survival pathway. To overcome these
challenges and understand the adopted effector down-
stream mechanism post oncogene knockdown, we hier-
archically created a well-deﬁned 200nm tri-block
nanocomplex with each sublayer contributing to a deﬁ-
nite function. The nanocomplex comprises of an enzy-
matically cleavable protein (gelatin) nanoparticle
encapsulated with a TKI (geﬁtinib) and surface func-
tionalized with an antibody (Cetuximab)-siRNA (Kras
G12C) conjugate. Detailed characterization revealed each
nanoparticle of the tri-block nanocomplex comprised of
w400 antibodies andw800 siRNA. We protected 14KDa
siRNA within 150KDa cetuximab and sandwiched it be-
tween antibody and gelatin nanoparticle to protect from
serum degradation, conﬁrmed using SDS-PAGE. To
investigate cellular activity, we incubated the nano-
complex in drug resistant Kras G12C mutant NSCLC
(H23 cells). The nanocomplex, when delivered to cyto-
plasm of the drug resistant H23 cells for oncogene
knockdown, sensitized the affected cells to the co-
delivered TKI. Knockdown of the oncogene was
conﬁrmed by monitoring the PI3K and MAPK down-
stream protein expression levels. Western blot results
indicated abrogation of activated PI3K and MAPK
pathway proteins. In vitro assays revealed 95% toxicity
for the nanocomplex containing 5mM geﬁtinib as against
0-10% toxicity for 5mM stand-alone geﬁtinib. rtPCR
showed downregulation of DUSP6, a known effect for
H23 cells with knocked down oncogene. Flow cytometry
results showed 2 fold higher internalization of the
nanocomplex compared to transfected siRNA. However,
in the absence of TKI, the nanocomplex showed no
toxicity suggesting the cells adapt to a parallel effector
pathway for survival, although phosphorylated Mek, Erk
and Akt were downregulated leading us to investigate a
possible survival mechanism. We hypothesized that the
downstream signaling is governed by Gab1 assisted
pathway. In H23 cells, activated ERK results in phos-
phorylation of Gab1 on serine and threonine residues
and forms Gab1-p85 PI3K complex that are adjacent to
p85 PI3K binding sites. Knocking down the oncogene
dephosphorylated Erk, and negated the complex forma-
tion. This further cascaded in tyrosine phosphorylation
at Tyr627 domain of Gab1, which is known to associate
with downstream of EGFR but upstream of Ras, to
regulate EGFR signaling through several positive feed-
back loops. We found that TKI binds to this speciﬁc
phosphotyrosine domain of Gab1, the domain that is
responsible for Gab1-Egfr association. In the absence of a
TKI, the feedback loop mediated via Gab1 provides a
route for survival but is sensitized by abrogation of
Gab1-Egfr complex formation post oncogene knockdown
when exposed to a TKI. The outcome of this study
